
ADS024:
An LPAR3-targeted
Biotherapeutic
ADS024:
An LPAR3-targeted
Biotherapeutic

ADS024:
An LPAR3-targeted
Biotherapeutic
ADS024:
An LPAR3-targeted
Biotherapeutic

ADS024:
An LPAR3-targeted
Biotherapeutic
ADS024:
An LPAR3-targeted
Biotherapeutic

ADS024:
An LPAR3-targeted
Biotherapeutic
ADS024:
An LPAR3-targeted
Biotherapeutic
ADS024 is a non engrafting, naturally occurring single strain live biotherapeutic product (SS-LBP).
It is an orally dosed, anti-inflammatory SS-LBP that produces a selective agonist of the G protein-coupled receptor (GPCR) Lysophosphatidic acid receptor 3 (LPAR3).
ADS024 is a non engrafting, naturally occurring single strain live biotherapeutic product (SS-LBP).
It is an orally dosed, anti-inflammatory SS-LBP that produces a selective agonist of the G protein-coupled receptor (GPCR) Lysophosphatidic acid receptor 3 (LPAR3).
THE TARGET, LYSOPHOSPHATIDIC ACID RECEPTOR 3 (LPAR3)
THE TARGET, LYSOPHOSPHATIDIC ACID RECEPTOR 3 (LPAR3)
THE TARGET, LYSOPHOSPHATIDIC ACID RECEPTOR 3 (LPAR3)
LPAR3 is a G-protein coupled receptor (GPCR) in the EDG family of receptors (S1PRs/LPARs) known to modulate inflammation.
LPAR3 is expressed in the brain and has genetic associations with biomarkers in Alzheimer’s Disease.
LPAR3 agonism is a novel disease-modifying approach to neurodegeneration.
LPAR3 is a G-protein coupled receptor (GPCR) in the EDG family of receptors (S1PRs/LPARs) known to modulate inflammation.
LPAR3 is expressed in the brain and has genetic associations with biomarkers in Alzheimer’s Disease.
LPAR3 agonism is a novel disease-modifying approach to neurodegeneration.
LPAR3 is a G-protein coupled receptor (GPCR) in the EDG family of receptors (S1PRs/LPARs) known to modulate inflammation.
LPAR3 is expressed in the brain and has genetic associations with biomarkers in Alzheimer’s Disease.
LPAR3 agonism is a novel disease-modifying approach to neurodegeneration.





POTENT AGONISM
ADS024 is cultured to produce a potent selective agonist of LPAR3.
ADS024 is then lyophilized to a powder form that can be dosed orally.
GI RELEASE
The LPAR3 agonist remains
stably associated with ADS024 until it is orally dosed.
Studies in mice show that > 99.9% of the SS-LBP does not survive transit through the GI tract.
BRAIN EFFICACY
ADS024 has shown efficacy
in an AD model and in multiple models of other neurodegenerative and neuroinflammatory diseases suggesting impact regardless of the cause of damage.
The preclinical dataset generated to date strongly supports moving into human testing in AD patients.
POTENT AGONISM
POTENT AGONISM
ADS024 is cultured to produce a potent selective agonist of LPAR3.
ADS024 is then lyophilized to a powder form that can be dosed orally.
ADS024 is cultured to produce a potent selective agonist of LPAR3.
ADS024 is then lyophilized to a powder form that can be dosed orally.
GI RELEASE
GI RELEASE
The LPAR3 agonist remains
stably associated with ADS024 until it is orally dosed.
Studies in mice show that > 99.9% of the SS-LBP does not survive transit through the GI tract.
The LPAR3 agonist remains
stably associated with ADS024 until it is orally dosed.
Studies in mice show that > 99.9% of the SS-LBP does not survive transit through the GI tract.
BRAIN EFFICACY
BRAIN EFFICACY
ADS024 has shown efficacy
in an AD model and in multiple models of other neurodegenerative and neuroinflammatory diseases suggesting impact regardless of the cause of damage.
The preclinical dataset generated to date strongly supports moving into human testing in AD patients.
ADS024 has shown efficacy
in an AD model and in multiple models of other neurodegenerative and neuroinflammatory diseases suggesting impact regardless of the cause of damage.
The preclinical dataset generated to date strongly supports moving into human testing in AD patients.



INVESTMENT AND PARTNERING
INVESTMENT AND PARTNERING
INVESTMENT AND PARTNERING
Adiso welcomes the opportunity to collaborate with like-minded investors and strategic partners who share our dedication to making a significant impact on the lives of Alzheimer's patients and their families.
ADS024 has a comprehensive patent portfolio and is available for partnering or investment.
You can contribute your expertise and valuable insights to help guide the development of products and solutions that align with your objectives.
Adiso welcomes the opportunity to collaborate with like-minded investors and strategic partners who share our dedication to making a significant impact on the lives of Alzheimer's patients and their families.
ADS024 has a comprehensive patent portfolio and is available for partnering or investment.
You can contribute your expertise and valuable insights to help guide the development of products and solutions that align with your objectives.
Adiso welcomes the opportunity to collaborate with like-minded investors and strategic partners who share our dedication to making a significant impact on the lives of Alzheimer's patients and their families.
ADS024 has a comprehensive patent portfolio and is available for partnering or investment.
You can contribute your expertise and valuable insights to help guide the development of products and solutions that align with your objectives.

